Humulin M3 (30/70) Cartridge (Insulin Human (Rdna))

Humulin M3 (30/70) is prescribed for adults and children with diabetes who require a combined basal and bolus insulin regimen.

• Management of type 1 diabetes mellitus when multiple daily injections are part of the treatment plan.
• Adjunct therapy for type 2 diabetes mellitus inadequately controlled with oral agents or basal insulin alone.
• Simplification of insulin therapy by providing both rapid‑acting and intermediate‑acting components in a single cartridge.
• Use in hospital or outpatient settings where a premixed insulin can reduce injection frequency.

• Insulin human (30/70) binds to insulin receptors on muscle, adipose and hepatic cells, activating the receptor tyrosine kinase pathway. This triggers downstream signaling that promotes translocation of GLUT‑4 transporters to the cell membrane, increasing glucose uptake, while simultaneously suppressing hepatic gluconeogenesis. The rapid‑acting fraction initiates glucose disposal within minutes, and the intermediate‑acting fraction sustains basal insulin activity for up to 24 hours.

Like all insulin products, Humulin M3 may cause adverse reactions. Reported events are grouped by frequency and severity.

Common

• Mild hypoglycemia with sweating, tremor, or brief confusion.
• Injection‑site redness, swelling, itching or mild pain.
• Lipohypertrophy at repeatedly used injection sites.
• Nausea or abdominal discomfort after injection.
• Transient headache occurring shortly after injection.

Serious

• Severe hypoglycemia needing assistance or medical treatment.
• Allergic reaction ranging from urticaria to anaphylaxis.
• Fluid retention, edema, or worsening heart failure.
• Persistent hyperglycemia suggesting dosing error or resistance.
• Serum‑sickness‑like hypersensitivity reaction with fever and joint pain.
• Unexplained weight gain indicating possible fluid overload.

When prescribing Humulin M3, clinicians should consider several precautionary measures to ensure safe use.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Monitor blood glucose closely during initiation, dose changes, or periods of illness.
• Adjust doses in patients prone to hypoglycemia, such as the elderly or those with irregular meals.
• Counsel patients on proper injection technique and site rotation to reduce lipodystrophy.
• Review concomitant medications that can mask hypoglycemia symptoms.
• Use caution in pregnancy; although category B, glycemic targets should be individualized.
• Evaluate cardiovascular status, as fluid retention may exacerbate heart failure.

Humulin M3 can interact with other agents that affect glucose levels or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment.
• Beta‑blockers that may mask hypoglycemia symptoms.
• High‑dose corticosteroids that increase insulin resistance.
• MAO‑inhibitors combined with sympathomimetic agents causing unpredictable glucose changes.

Use with caution

• Oral antidiabetic drugs (e.g., sulfonylureas, meglitinides) that may potentiate hypoglycemia.
• ACE inhibitors or ARBs, which can enhance insulin sensitivity.
• Thiazide diuretics that may raise blood glucose.
• Alcohol consumption, which can cause delayed hypoglycemia.